(Q79448439)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17186017%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

review article

1 reference

title

Chemoprevention of breast cancer with selective oestrogen-receptor modulators (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17186017%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

1 reference

1

V Craig Jordan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17186017%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17186017%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

published in

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17186017%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17186017%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17186017%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

page(s)

46-53

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17186017%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrc2048

23 December 2019

exact match

0 references

cites work

Tamoxifen: a most unlikely pioneering medicine

1 reference

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

31 March 2020

1 reference

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually

31 March 2020

1 reference

Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer

31 March 2020

1 reference

Chemosuppression of breast cancer with tamoxifen: laboratory evidence and future clinical investigations

31 March 2020

1 reference

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

31 March 2020

1 reference

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

31 March 2020

1 reference

Antagonism of estrogen action with a new benzothiophene derived antiestrogen

31 March 2020

1 reference

Effects of anti-estrogens on bone in castrated and intact female rats

31 March 2020

1 reference

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

31 March 2020

1 reference

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

31 March 2020

1 reference

Chemoprevention: drug pricing and mortality: the case of tamoxifen.

31 March 2020

1 reference

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

31 March 2020

1 reference

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

31 March 2020

1 reference

Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women

31 March 2020

1 reference

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

31 March 2020

1 reference

Sequence and expression of human estrogen receptor complementary DNA

31 March 2020

1 reference

Cloning of a novel receptor expressed in rat prostate and ovary

31 March 2020

1 reference

Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta

31 March 2020

1 reference

Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia.

31 March 2020

1 reference

Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest

31 March 2020

1 reference

Survival versus apoptotic 17beta-estradiol effect: role of ER alpha and ER beta activated non-genomic signaling.

31 March 2020

1 reference

Transcription activation by the human estrogen receptor subtype beta (ER beta) studied with ER beta and ER alpha receptor chimeras

31 March 2020

1 reference

Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists

31 March 2020

1 reference

The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens

31 March 2020

1 reference

Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites

31 March 2020

1 reference

Sequence and characterization of a coactivator for the steroid hormone receptor superfamily

31 March 2020

1 reference

Coregulator function: a key to understanding tissue specificity of selective receptor modulators

31 March 2020

1 reference

Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents

31 March 2020

1 reference

Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-alpha and estrogen receptor-beta: correlations with biological character and distinct differences among SRC coactivator family members

31 March 2020

1 reference

The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen

31 March 2020

1 reference

Molecular basis of agonism and antagonism in the oestrogen receptor

31 March 2020

1 reference

The expanding cosmos of nuclear receptor coactivators

31 March 2020

1 reference

E3 ubiquitin ligases as cancer targets and biomarkers

31 March 2020

1 reference

Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription

31 March 2020

1 reference

Studies on the mechanism of action of the nonsteroidal antioestrogen tamoxifen (I.C.I. 46,474) in the rat.

31 March 2020

1 reference

The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators

31 March 2020

1 reference

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer

31 March 2020

1 reference

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

31 March 2020

1 reference

A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity

31 March 2020

1 reference

Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships

31 March 2020

1 reference

Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model

31 March 2020

1 reference

Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen

31 March 2020

1 reference

Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.

31 March 2020

1 reference

Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells

31 March 2020

1 reference

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

31 March 2020

1 reference

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

31 March 2020

1 reference

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment

31 March 2020

1 reference

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

31 March 2020

1 reference

Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018

31 March 2020

1 reference

Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance

31 March 2020

1 reference

Disposition mechanisms of raloxifene in the human intestinal Caco-2 model

31 March 2020

1 reference

Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients.

31 March 2020

1 reference

Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer

31 March 2020

1 reference

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

31 March 2020

1 reference

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

31 March 2020

1 reference

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

31 March 2020

1 reference

Breast cancer prevention—clinical trials strategies involving aromatase inhibitors

31 March 2020

1 reference

Prevention strategies with aromatase inhibitors

31 March 2020

1 reference

Discovery, clinical development, and therapeutic uses of bisphosphonates

31 March 2020

1 reference

Tissue-specific promoters regulate aromatase cytochrome P450 expression

31 March 2020

1 reference

Aromatase--a brief overview

31 March 2020

1 reference

Coactivation of liver receptor homologue-1 by peroxisome proliferator-activated receptor gamma coactivator-1alpha on aromatase promoter II and its inhibition by activated retinoid X receptor suggest a novel target for breast-specific antiestrogen th

31 March 2020

1 reference

Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells.

31 March 2020

1 reference

Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition

31 March 2020

1 reference

Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers

31 March 2020

1 reference

A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer

31 March 2020

1 reference

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

31 March 2020

1 reference

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial

31 March 2020

1 reference

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

31 March 2020

1 reference

Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk.

31 March 2020

1 reference

Necropsy diagnosis of endometrial cancer and detection-bias in case/control studies

31 March 2020

1 reference

Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis

31 March 2020

1 reference

Tamoxifen does not form detectable DNA adducts in white blood cells of breast cancer patients.

31 March 2020

1 reference

Understanding the genotoxicity of tamoxifen?

31 March 2020

1 reference

17-Beta-estradiol induces transformation and tumorigenesis in human breast epithelial cells

31 March 2020

1 reference

Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens

31 March 2020

1 reference

Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene

31 March 2020

1 reference

Molecular biology. Little molecules with big goals

31 March 2020

1 reference

Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases

31 March 2020

1 reference